Depression is one of the most frequent and devastating psychiatric diseases with a substantial bur-den for patients and society. It is specifically associated with dysfunctional activity in brain networks subserving cognitive control of emotional information processing. Normalization of this activity is a hallmark of various treatment approaches. Computerized training of cognitive control has shown antidepressant effects in experimental lab settings and small clinical pilot trials. However, motiva-tion, treatment adherence, and access for patients are major challenges that limit its broader use. To address these challenges, we developed a software application (de:)press®) that integrates gamification elements in a standard cognitive control task to support motivation, usage time, usabil-ity, and therefore symptom reduction. In a previous pilot trial, we were able to document that de:)press® is superior to a non-gamified standard cognitive control training in reducing depression symptomatology. Based on these data, we now designed a full-size confirmatory trial for the pur-pose of testing the hypothesis that de:)press® provides a positive healthcare effect by means of reduction in depression severity compared to treatment as usual (TAU). In this randomized, con-trolled, clinical trial 112 patients will be randomized to the intervention group (IG) with de:)press® additional to TAU, or the control group (CG) receiving only TAU. For a period of 6 weeks, the IG is provided with de:)press®. To prove a stable efficacy of de:)press®, the primary endpoint is the dif-ference in the Montgomery-Åsberg Depression Scale (MADRS) change 4 weeks after the end of training between IG and CG.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Enrollment
112
Patients will receive de:)press for the duration of six weeks. They will be encourages to use the app at least three times a week, up to once per day.
University Hospital Tübingen
Tübingen, Baden-Wurttemberg, Germany
RECRUITINGMADRS
Difference in symptom severity-reduction (MADRS) between IG and CG at the final examination.
Time frame: 10 weeks
Response rate
Response rate (MADRS ≤ 50%) at the final examination.
Time frame: 10 weeks
Remission rate
MADRS score ≤ 10.
Time frame: 10 weeks
IDS-SR reduction
Reduction (IG vs. CG) of IDS-SR score during treatment phase and at final examination.
Time frame: 10 weeks
WHO-5 changes
Changes of well-being according to WHO-5 during treatment period and at final examination.
Time frame: 10 weeks
WPAI changes
Changes of functionality according to WPAI during treatment period and at final examination.
Time frame: 10 weeks
Training sessions
Number of completed training sessions in IG.
Time frame: 6 weeks
Adverse events
Adverse events.
Time frame: 10 weeks
Self-esteem
Influence of RSES on the primary endpoint.
Time frame: 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.